| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acceptance of Evidence Transfer Within German Early Benefit Assessment of New Drugs for Pediatric and Adolescents Target Populations
|
Pick, Georgia
|
|
|
43 |
5 |
p. 521-553
|
artikel
|
| 2 |
A Taxonomy for Assessing Whether HRQoL Value Sets Are Obsolete
|
Norman, Richard
|
|
|
43 |
5 |
p. 473-481
|
artikel
|
| 3 |
Correction: De Novo Cost‑Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation
|
Gal, Peter
|
|
|
43 |
5 |
p. 595-596
|
artikel
|
| 4 |
Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection
|
Zeevat, Florian
|
|
|
43 |
5 |
p. 569-582
|
artikel
|
| 5 |
EQ-5D-5L or EQ-HWB-S: Which is the Better Instrument for Capturing Spillover Effects in Parental Carers of Children with COVID-19?
|
Zhou, Wenjing
|
|
|
43 |
5 |
p. 555-567
|
artikel
|
| 6 |
Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria
|
Donoghue, Jeremiah
|
|
|
43 |
5 |
p. 499-508
|
artikel
|
| 7 |
Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI’s Gene Therapy Access Model
|
Zemplenyi, Antal
|
|
|
43 |
5 |
p. 583-594
|
artikel
|
| 8 |
Prognostic Testing for Prostate Cancer—A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice
|
Fridhammar, Adam
|
|
|
43 |
5 |
p. 509-520
|
artikel
|
| 9 |
Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology
|
Kramer, Astrid
|
|
|
43 |
5 |
p. 483-497
|
artikel
|
| 10 |
Uncertainty in Matching-Adjusted Indirect Comparisons Using Real-World Evidence: Evidence Assessment Group Perspective
|
Uteh, Cyril Onwuelazu
|
|
|
43 |
5 |
p. 469-472
|
artikel
|
Tijdschrift beschrijving